Literature DB >> 16736177

[Pitfalls in the classification of liver tumors].

C Wittekind1.   

Abstract

Up-to-date clinical oncology requires an exact and standardized way of classifying tumors. Experience shows that mistakes can occur more frequently than generally expected during the classification procedure and documentation. Several possible sources of errors will be mentioned in this contribution. Errors can occur in localizing the exact site of the primary tumor, which can lead to an incorrect classification of metastases in lymph nodes, e.g., N1/pN1 instead of M1/pM1. Difficulties in histological typing of liver tumors, particularly in the differential diagnosis between hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) can be minimized by using immunohistochemistry. The grading of HCC can be performed according to two systems, namely those of Edmondson and Steiner and of the WHO. The grading system used should be indicated. For estimating the anatomical extent of primary liver tumors, vascular invasion is an important parameter. Resection margins have to be thoroughly examined to aim at an most exact residual tumor classification.

Entities:  

Mesh:

Year:  2006        PMID: 16736177     DOI: 10.1007/s00292-006-0834-1

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  6 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  International Union Against Cancer. Classification of isolated tumor cells and micrometastasis.

Authors:  P Hermanek; R V Hutter; L H Sobin; C Wittekind
Journal:  Cancer       Date:  1999-12-15       Impact factor: 6.860

Review 3.  [The importance of immunohistochemistry for the diagnosis of cholangiocarcinomas].

Authors:  F Länger; R von Wasielewski; H H Kreipe
Journal:  Pathologe       Date:  2006-07       Impact factor: 1.011

4.  The pathologist and the residual tumor (R) classification.

Authors:  P Hermanek; C Wittekind
Journal:  Pathol Res Pract       Date:  1994-02       Impact factor: 3.250

5.  TNM residual tumor classification revisited.

Authors:  Christian Wittekind; Carolyn C Compton; Frederick L Greene; Leslie H Sobin
Journal:  Cancer       Date:  2002-05-01       Impact factor: 6.860

6.  Reconsideration of the lymph node metastasis pattern (N factor) from intrahepatic cholangiocarcinoma using the International Union Against Cancer TNM staging system for primary liver carcinoma.

Authors:  Y Nozaki; M Yamamoto; I Ikai; Y Yamamoto; N Ozaki; H Fujii; K Nagahori; Y Matsumoto; Y Yamaoka
Journal:  Cancer       Date:  1998-11-01       Impact factor: 6.860

  6 in total
  38 in total

1.  Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications.

Authors:  Chi Zhang; Li-Xin Liu; Zhao-Ru Dong; Guo-Ming Shi; Jia-Bin Cai; Peng-Fei Zhang; Ai-Wu Ke; Jing-Xian Yu; Jian Zhou; Jia Fan
Journal:  Tumour Biol       Date:  2014-11-13

2.  Sox2 expression predicts poor survival of hepatocellular carcinoma patients and it promotes liver cancer cell invasion by activating Slug.

Authors:  Chun Sun; Lu Sun; Yan Li; Xiaonan Kang; Shu Zhang; Yinkun Liu
Journal:  Med Oncol       Date:  2013-02-21       Impact factor: 3.064

3.  Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma.

Authors:  Yang Xu; Venugopal Chenna; Chaoxin Hu; Hai-Xiang Sun; Mehtab Khan; Haibo Bai; Xin-Rong Yang; Qin-Feng Zhu; Yun-Fan Sun; Anirban Maitra; Jia Fan; Robert A Anders
Journal:  Clin Cancer Res       Date:  2011-08-25       Impact factor: 12.531

4.  Overexpressions of CK2β and XIAP are associated with poor prognosis of patients with cholangiocarcinoma.

Authors:  Fan Zhou; Jiewei Xu; Guoping Ding; Liping Cao
Journal:  Pathol Oncol Res       Date:  2013-07-05       Impact factor: 3.201

5.  Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis.

Authors:  Zi-Jun Gong; Jian-Wen Cheng; Pin-Ting Gao; Ao Huang; Yun-Fan Sun; Kai-Qian Zhou; Bo Hu; Shuang-Jian Qiu; Jian Zhou; Jia Fan; Xin-Rong Yang
Journal:  Oncologist       Date:  2019-03-25

6.  Upregulation of bone morphogenetic protein 4 is associated with poor prognosis in patients with hepatocellular carcinoma.

Authors:  Xiaodong Guo; Lu Xiong; Lin Zou; Jingmin Zhao
Journal:  Pathol Oncol Res       Date:  2012-02-15       Impact factor: 3.201

7.  Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China.

Authors:  Jia Fan; Guang-Shun Yang; Zhi-Ren Fu; Zhi-Hai Peng; Qiang Xia; Chen-Hong Peng; Jian-Ming Qian; Jian Zhou; Yang Xu; Shuang-Jian Qiu; Lin Zhong; Guang-Wen Zhou; Jian-Jun Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-21       Impact factor: 4.553

8.  BRCA1-associated protein 1 serves as a tumor suppressor in hepatocellular carcinoma by deubiquitinating and stabilizing PTEN.

Authors:  Xuxiao Chen; Ao Huang; Yupeng Wang; Feiyu Chen; Bo Hu; Xin Zhang; Yunfan Sun; Jian Wang; Jianwen Cheng; Pengxiang Wang; Yuan Ji; Shuangjian Qiu; Jia Fan; Jian Zhou; Xinrong Yang
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

9.  Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinoma.

Authors:  Zhi-Qiang Hu; Hao-Yang Xin; Chu-Bin Luo; Jia Li; Zheng-Jun Zhou; Ji-Xue Zou; Shao-Lai Zhou
Journal:  Cancer Immunol Immunother       Date:  2020-08-06       Impact factor: 6.968

10.  The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma.

Authors:  Ledu Zhou; Yun Huang; Jingdong Li; Zhiming Wang
Journal:  Med Oncol       Date:  2009-03-20       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.